Recon: Medicare unveils discounted drug prices after first round of negotiation; FDA approves Gilead’s primary biliary cholangitis drug
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyReimbursementUnited States